Beyond biologics: Amgen bets new drugs will pay dividend
Amgen executives believe the biotech giant will grow substantially in the next decade, pursuing drugs that treat major melanoma and bone loss.
ValueClick defies its skeptics
ValueClick is out to prove to investors that it still has some pluck after more than a decade in the digital marketing business.
UCSB engineering recruits Bell Labs veteran
UC Santa Barbara has named a new dean of its College of Engineering.
Pouring in millions: Japanese food oil venture proposed for harbor area
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Editorial: Coming stealth crisis — rising unemployment costs for you
If you think, as most of us do, that all that’s needed to fix California’s problems is a deal between Gov. Jerry Brown and the Republican minority in the Legislature, think again. Beyond the budget, a perennial circus show that crowds the middle ring of state politics, there are myriad problems that plague the Golden Read More →
Strength in numbers: Thousand Oaks firm taps crowds
Invested.in helps individuals and organizations tap their social networks for funding.
